

Clinical Trial Protocol

Iranian Registry of Clinical Trials

13 Jun 2026

Evaluation of zinc sulfate effect in prevention of chemotherapy-induced mucositis in Patients with cancer referred to Emam Ali Hospital in 2008-2009

Protocol summary

Summary

This study has been designed to evaluate the effect of zinc Sulphate in prevention of chemotherapy-induced mucositis. A total of 50 patients with chemotherapy-induced mucositis are randomly assigned into intervention or control group. The intervention group received three zinc sulfate capsules daily (220-mg made by Alhavi Co.) in addition to conventional mucositis treatment and the control group received three placebo capsules daily. for 6 months. Intensity of Mucositis, Xerostomia, and pain are evaluated a week before initiation of chemotherapy, during chemotherapy phase until two weeks after the end of chemotherapy phase, once a week compared between groups.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201101023133N3**

Registration date: **2011-02-01, 1389/11/12**

Registration timing: **retrospective**

Last update:

Update count: **0**

Registration date

2011-02-01, 1389/11/12

Registrant information

Name

Fateme Arbabi Kalati

Name of organization / entity

Dental school of Zahedan

Country

Iran (Islamic Republic of)

Phone

+98 54 1244 1814

Email address

farbabi@razi.tums.ac.ir

Recruitment status

Recruitment complete

Funding source

Zahedan University of Medical Sciences

Expected recruitment start date

2008-08-22, 1387/06/01

Expected recruitment end date

2009-08-23, 1388/06/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation of zinc sulfate effect in prevention of chemotherapy-induced mucositis in Patients with cancer referred to Emam Ali Hospital in 2008-2009

Public title

Evaluation of zinc sulfate effect in prevention of chemotherapy-induced mucositis in Patients with cancer referred to Emam Ali Hospital in 2008-2009

Purpose

Prevention

Inclusion/Exclusion criteria

Inclusion criteria: chemotherapy treatment with a regimen that had the same mucositis probability, Karnovsky performance status case equal or more than 60, life expectancy equal to or more than 6 months, White Blood Cell count equal to or more than 1500 and platelet count equal to or more than 100000/ μ L Exclusion criteria: radiotherapy in the head and neck region, including nasopharynx, oropharynx, and larynx previously or simultaneously, previous head and neck

surgery due to malignancy, use of dentures, pregnancy, infection

Age

From **18 years** old

Gender

Both

Phase

3

Groups that have been masked

No information

Sample size

Target sample size: **50**

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Double blinded

Blinding description

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Zahedan University of Medical Sciences

Street address

Zahedan University of Medical Sciences, Pardis,
Zahedan

City

Zahedan

Postal code

Approval date

2010-12-29, 1389/10/08

Ethics committee reference number

89-2870

Health conditions studied

1

Description of health condition studied

Chemotherapy-induced mucositis

ICD-10 code

K13.7

ICD-10 code description

Other and unspecified lesions of oral mucosa

Primary outcomes

1

Description

Mucositis

Timepoint

Two weeks after initiation of chemotherapy and every two weeks until

Method of measurement

The patients are examined under a headlight, using dental explorers and mirrors. Data were recorded. Oral mucositis patients were labelled from 0 to 4 ,using World Health.

Secondary outcomes

1

Description

Pain

Timepoint

Two weeks after initiation of chemotherapy and every two weeks until the end of chemotherapy phase

Method of measurement

The patients are examined under a headlight, using dental explorers and mirrors. Data were recorded. Oral mucositis patients were labelled from 0 to 4 ,using World Health.

2

Description

Xerostomia

Timepoint

Two weeks after initiation of chemotherapy and every two weeks until the end of chemotherapy phase

Method of measurement

The patients are examined under a headlight, using dental explorers and mirrors. Data were recorded

3

Description

Quality of life

Timepoint

Two weeks after initiation of chemotherapy and every two weeks until the end of chemotherapy phase

Method of measurement

Quality of life a questionnaire (EORTC LQ-OES18) is filled out each meeting individually by the dental student

Intervention groups

1

Description

Control group/Placebo: three placebo capsules daily (Alhavi Co.), initiation of chemotherapy until the end of chemotherapy phase.

Category

Prevention

2

Description

Intervention group/Drug: three 220-mg zinc sulfate capsules daily (Alhavi Co.), initiation of chemotherapy until the end of chemotherapy phase

Category

Prevention

Recruitment centers

1

Recruitment center

Name of recruitment center

Zahedan Emam Ali Hospital

Full name of responsible person

Fateme Arbabi-kalati (assistant of professor , a specialist of oral medicine)

Street address

Emam Ali Hospital-Zahedan

City

Zahedan

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Zahedan University of Medical Sciences

Full name of responsible person

Dr sagheb (Vice-chancellor for Research, Zahedan University of Medical Sciences

Street address

Zahedan University of Medical Sciences, Pardis, Khalij Fars Boulevard, Zahedan

City

Zahedan

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Zahedan University of Medical Sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact

Name of organization / entity

Zahedan University of Medical Sciences

Full name of responsible person

Marzie Deghatipour

Position

Dental student

Other areas of specialty/work

Street address

Faculty of Dentistry, Koye Tirandazi Street, Zahedan

City

Zahedan

Postal code

Phone

+98 54 1241 4004

Fax

Email

marzie_deghatipour@yahoo.com

Web page address

www.zaums.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity

Zahedan University of Medical Sciences, Faculty of Dentistry

Full name of responsible person

Dr Fateme Arbabi-kalati

Position

Assistant Professor of Oral Medicine

Other areas of specialty/work

Street address

Faculty of Dentistry, Koye Tirandazi Street, Zahedan

City

Zahedan

Postal code

Phone

+98 54 1241 4004

Fax

Email

farbabi@razi.tums.ac.ir

Web page address

www.zaums.ac.ir

Person responsible for updating data

Contact

Name of organization / entity

Zahedan University of Medical Sciences

Full name of responsible person

Dr Fateme Arbabi-kalati

Position

Assistant Professor of Oral Medicine

Other areas of specialty/work

Street address

Faculty of Dentistry, Koye Tirandazi street, Zahedan

City

Zahedan

Postal code

Phone

+98 54 1241 4004

Fax

Email

farbabi@razi.tums.ac.ir

Web page address

www.zaums.ac.ir

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty